1. Introduction {#s0005}
===============

Schistosomiasis, a parasitic disease caused by blood helminthes of genus *Schistosoma*, is still considered one of the major threatening health diseases in water based world\'s tropical regions ([@b0135]), particularly the developing countries with significant poverty and public health problems ([@b0015]), and in 2013, [@b0155] estimated the need of treatment to at least 230 million people per year against schistosomiasis.

Adult flukes of the parasite are not the main cause of the injuries in the mammalian host body ([@b0090]), but the massive egg production by the female worms, that reaches hundreds to thousands of eggs per day, is the major stimulant of chronic lesions, as it results in formation of granuloma in different body organs such as gut, intestine, liver, spleen, bladder and lungs ([@b0010], [@b0150]).

Enlargement of both the liver ([@b0035]) and spleen ([@b0020], [@b0035]) is called hepatosplenomegaly, a major pathological symptom of chronic schistosomiasis ([@b0030]). Spleen, the biggest and the main peripheral immune system organ, is one of the important affected organs by schistosomiasis in variable degrees correlated with the hepatic portal circulation ([@b0150]).

Treatment of schistosomiasis is still based on praziquantel (PZQ), a drug known by its effectiveness against different *Schistosoma* specie ([@b0095]), however, its low absorption through the intestine because it is less soluble in water ([@b0110]) and its metabolism results in production of a less effective compound and thus must be administrated in higher concentrations ([@b0115]), additionally, the influence of the drug is inadequate against schistosomules and immature worms, so it is unsuitable for mass treatment in high endemic regions ([@b0055]). These factors in addition to the parasite resistance develops against the drug ([@b0025]) were of the reasons that motivated scientists and physicians to search for alternative safe and more effective treatments to improve oral absorption of PZQ and/or replace it ([@b0170], [@b0005]).

Recently, nanotechnology is being used globally in different fields, nanoparticles (NPs) of some metals or metal oxides are now widely used as drugs to treat different diseases and improve human health due to their antimicrobial actions; these tiny molecules of specific chemical and physical features have shown antibacterial, antiviral and antiparasite activities ([@b0060], [@b0100]). Gold and silver NPs and oxide NPs of zinc, titanium and magnesium have presented antileishmanial activities ([@b0100]), in addition, [@b0045], [@b0050] have demonstrated the antischistosomal activity of gold nanoparticles (GNPs) in liver and brain of mice respectively. Therefore, the present study is a continuation of serial studies of [@b0045], [@b0050] to emphasize the antischistosomal action of GNPs on the splenic tissue of mice infected with the *Schistosoma mansoni*.

2. Materials and methods {#s0010}
========================

2.1. Animals and infection {#s0015}
--------------------------

Male Swiss albino mice were bred in Schistosome Biological Supply Center at Theodor Bilharz Research Institute, Imbaba, Giza, Egypt. In our study, 24 mice were maintained under specified pathogen-free conditions and fed on standard diet. Diet and water were provided *ad libitum*.

By subcutaneous injection; mice (9--11) weeks of age, were infected with 100 ± 10 *S. mansoni* cercarie ([@b0125]). Cercarie were obtained from Schistosome Theodor Bilharz Research Institute.

2.2. Gold Nano-Particles (GNPs) {#s0020}
-------------------------------

According to [@b0145], GNPs have been prepared by chemical reduction method. "HAuCl~4~" solution has been used as Au^3+^ ions precursor; while sodium citrate has been used as both of mild reducing and stabilizing agent. The color of the solution slowly turned into faint pink color, indicating the reduction of the Au^3+^ ions to Au NPs.

By transmission electron microscopy (TEM); size and morphology of GNPs were determined ([Fig. 1](#f0005){ref-type="fig"}). Samples for TEM were prepared using the clear solution of NPs. The sample solution was put on a formvar coated grid. On this grid, a drop of the sample solution (containing dispersed NPs) was placed and allowed to air-dry. A TEM picture was taken by a JOEL JEM 2000 EX200 microscope.Figure 1Transmission electron microscopy image of gold nanoparticles illustrates their shape and size. Scale bar indicates 100 nm.

2.3. Animal groups {#s0025}
------------------

Experimental animals were divided into 4 groups; each of 6 mice. First group was considered as non-infected control group where the animals were orally received 100 μl water/mouse for 10 days. The remaining animals were infected with 100 ± 10 *S. mansoni* cercarie then divided into 3 groups, 46 days post-infection (*p.i.*).

One of these was infected (untreated). In addition, one of the remaining 2 infected groups received i.p. injection of 100 μl GNPs (1 mg/kg mice body weight), twice per week on day 46 and day 49 *p.i.*. On day 46 *p.i.* at an interval of 24 h for 2 days; the infected animals of last fourth group were orally administered 100 μl of PZQ (600 mg/kg body weight).

2.4. Histological investigations {#s0030}
--------------------------------

On day 56 *p.i.* and GNPs injection, the animals were killed by fast decapitation. Fragments of spleen were immediately removed, fixed in 10% formalin, dehydrated, embedded in paraffin, sectioned and stained with haematoxylin and eosin for histopathological studies.

2.5. Biochemical parameters {#s0035}
---------------------------

Spleen was immediately excised and weighted then homogenized immediately to give 50% (w/v) homogenate in ice-cold Tis-HCl buffer ([@b0140]). The homogenate was centrifuged at 500 × g for 10 min. The supernatant (10%) was used for estimation of glutathione, nitrite/nitrate and malondialdehyde.

The glutathione (GSH) level in intestine and spleen was determined by the method of [@b0065], in addition, the nitrite/nitrate and malondialdehyde (MDA) levels were assayed according to the method of [@b0085] and [@b0120], respectively.

2.6. Spleen index {#s0040}
-----------------

The spleen index was calculated by (ratio of spleen weight in mg/mouse to body weight in g/mouse), where; in all groups each mouse and its spleen were weighed.

2.7. Statistical analysis {#s0045}
-------------------------

The obtained data were presented as means ± standard error. One-way ANOVA was carried out, and the statistical comparisons among the groups were performed with Duncan's test using a statistical package program (SPSS version 17.0). *P* ⩽ 0.05 was considered as low, moderate and highly significant for all statistical analysis in this study.

3. Results {#s0050}
==========

*S. mansoni* induced a significant reduction in splenic GSH levels versus non-infected group as shown in [Table 1](#t0005){ref-type="table"}. Moreover, GNPs treatment at a dose level of (1 mg/kg mice body weight), twice per week on day 46 and day 49 *p.i.*; elevated GSH level significantly (*P* ⩽ 0.05) in the investigated spleen tissue as compared to schistosome infected mice. Likewise, PZQ gavage on day 46 *p.i.*at an interval of 24 h for 2 days resulted in a significant increase in splenic GSH level versus infected group (see [Table 1](#t0005){ref-type="table"}).Table 1Effect of GNPs on glutathione (GSH), nitrite/nitrate, and malondialdehyde (MDA) levels in splenic homogenate of mice infected with *S. mansoni*.GroupSplenic GSH (mg/g)Splenic nitrite/nitrate (μmol/g)Splenic MDA (nmol/g)Non-infected (-GNPs)52.32 ± 1.8996.58 ± 2.3328.31 ± 1.24Infected (-GNPs)16.26 ± 1.05^a^243.6 ± 3.24^a^79.68 ± 2.00^a^Infected (+1 mg/kg GNPs)26.91 ± 1.95^ab^189.2 ± 2.59^ab^58.07 ± 2.23^ab^Infected (+PZQ)22.69 ± 1.23^ab^200.4 ± 4.89^ab^53.72 ± 3.39^ab^[^1]

Data tabulated in [Table 1](#t0005){ref-type="table"} revealed that *S. mansoni* infection caused a significant elevation at *P* ⩽ 0.05 in levels of nitrite/nitrate and MDA in spleen as compared to non-infected group. On the other hand, the levels of nitrite/nitrate and MDA showed a significant reduction in splenic tissues as a result of GNPs and PZQ treatment versus infected group.

[Fig. 2](#f0010){ref-type="fig"} showed the histological picture of spleen; [Fig.2](#f0010){ref-type="fig"}A & B revealed normal spleen architecture where white and red pulps surrounded by a capsule of dense connective tissue. Since, white pulp is composed of a central, T-cell rich zone, and a periarterial lymphoid sheath surrounded by B-cell-rich primary follicles; the white pulp enlarged due to cellular proliferation and the limit between white and red pulps started to disappear; moreover, splenomegaly was observed as a result of schistosome infection ([Fig.2](#f0010){ref-type="fig"}C & D). Gold nanoparticles (1 mg/kg b. wt.) injection to schistosome infected induced significant improvements in the histological picture of spleen; with some histological impairment was still observed ([Fig.2](#f0010){ref-type="fig"}E & F). In the same manner, PZQ treatment induced significant improvements in spleen architecture of schistosome infected mice ([Fig.2](#f0010){ref-type="fig"}G & H).Figure 2Histological changes in splenic tissue of uninfected, and untreated and treated mice infected with *Schistosoma mansoni* on day 56 post-infection. (A & B) Uninfected spleen with normal architecture. (C & D) Spleen tissue of mice in *S. mansoni* infected group, showing splenomegaly, and enlargement of the white pulp indicated by cellular prolifertation, and gradual disappearance of the boundary between white and red pulps. (E&F) Spleen tissue of mice in *S. mansoni* infected groups treated with 1 mg GNPs/kg b. wt., exhibiting significant improvements in the histological architecture of the spleen, and less tissue damage. (G & H) Spleen of mice in infected group treated with PZQ, showing significant improvements in the spleen tissue with fewer lesions. Sections were stained with hematoxylin and eosin; scale bar = 50 μm.

Spleen index was calculated in [Table 2](#t0010){ref-type="table"}, infection resulted in a significant increase in spleen index as compared to non-infected control group. On the other hand, a significant decrease was recorded in spleen index as a result of GNPs injection and PZQ treatment versus schistosome-infected group.Table 2Effect of GNPs on the spleen index of mice infected with *S. mansoni*.GroupSpleen index (mg/g)Non-infected (-GNPs)4.18 ± 0.34Infected (-GNPs)15.13 ± 1.18^a^Infected (+1 mg/kg GNPs)9.80 ± 0.79^ab^Infected (+PZQ)9.16 ± 0.77^ab^[^2]

4. Discussion {#s0055}
=============

In the present study, GNPs treatment decreased splenic levels of nitrite/nitrate and MDA significantly; moreover, the nanoparticles increased GSH level significantly in intestine and spleen of the schistosome infected mice. Our results are in agreement on the protective role of GNPs on body tissues with ([@b0105], [@b0070], [@b0075], [@b0040], [@b0020], [@b0045], [@b0050]).

The oxidative status in bilharziasis was previously studied in organs such as liver, kidneys, gut and, to a lesser extent, spleen ([@b0105], [@b0070], [@b0075], [@b0020]). Since; it was previously observed that *S. mansoni* infection may induce oxidative stress in spleen ([@b0070], [@b0075], [@b0020]).

[@b0070] and [@b0020] deduced that spleen of schistosome-infected mice showed a significant increment in lipid peroxidation and nitric oxide levels and a significant decrease in vitamin E, GSH levels, and superoxide dismutase activity, where the oxidative processes occur at the inflammation site and are involved in the damaging effects of schistosomiasis so free radicals may be a major component of the disease. In the same manner; [@b0040] observed that decreased non-enzymatic antioxidant capacity in spleen.

Spleen is considered as one of the main affected organs during the schistosomiasis due to increased eosinophil peroxidase activity and imbalance in the antioxidant defense mechanisms ([@b0080]). In addition, some reports cleared that *S. mansoni* infection may imbalance oxidative parameters by different causes or mechanisms such as egg deposition, changes in vascular tone and soluble immune mediators ([@b0165], [@b0130], [@b0160]). [@b0045], [@b0050] found that GNPs showed an anti-schistosomal effect in brain and liver of mice. GNPs decreased nitrite/nitrate and MDA levels while, it increased the level of GSH in brain and liver homogenates; where, attributed these results to GNPs ability to scavenge free radicals.

Our results revealed that GNPs improved significantly; the splenic impairments induced by schistosomiasis. Likewise, GNPs showed a significant decrease in spleen index as compared to infected group. [@b0070] reported that histopathological observations revealed a large number of megakaryocytes in the spleen, and [@b0020] deduced that the infection induced splenic enlargement. In addition, disorganized red and white pulps were found in splenic tissue of the schistosomal infected mice. Moreover, GNPs at different doses showed an anti-bilharziasis activity in our previous work, where, GNPs ameliorated effects on schistosomiasis and improved the histopathological changes in both investigated organs "brain and liver" ([@b0045], [@b0050]).

5. Conclusion {#s0060}
=============

This study provides information for raising the interesting possibility that gold nanoparticles eventually have therapeutic potential against splenic disorders induced by *S. mansoni* infection. Therefore, the loading of antischistosomal drugs on nanocarriers may be the aim for the future work in this field to evaluate the therapeutic possibility of such drug delivery system.
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[^1]: Values are means ± SE. a: Significant against (non-infected) control group at *P* ⩽ 0.05, b: Significant against infected control group at *P* ⩽ 0.05, *n* = 6.

[^2]: Values are means ± SE. a: Significant against (non-infected) control group at *P* ⩽ 0.05, b: Significant against infected control group at *P* ⩽ 0.05, *n* = 6.
